Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Election/Restrictions
Applicant’s election without traverse of species: SEQ ID NO: 16, 28, 18, 28, 13, 27, 11, 12, and pancreatic ductal adenocarcinoma in the reply filed 08/07/2026 is acknowledged.
Claims 3-6, 11, 13-15, 18-19 are withdrawn from consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions and species, there being no allowable generic or linking claims. Election was made in the reply filed 08/07/2026.
Claims 1-2, 7-10, 12, 17, and 20 are now under consideration in the instant Office Action.
Claim Objections
Claim 1 is objected to because of the following informalities: the phrase “variable domain” is followed by a “VH” or a “VL”. These abbreviations do not acronymize the term that precedes it, nor is it clear that they belong to the same term. Appropriate correction is required.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1-2, 7-10, 12, 17, and 20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Instant claims 1-2, 7-10, 12, 17, and 20 recite the terms “variable domain VH”, “variable domain VL”, “VH domain”, and “VL domain” interchangeably throughout the claims. According to the instant specification, these terms refer to distinct aspects of the binding region. This is also evidenced by the various distinct sequences attributed to each term. The use of these terms interchangeably renders the instant claims unclear as they do not all share the same identity.
Regarding claim 1, the phrase "such as" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d).
Claims 1-2, 7, and 9-10 use the transitional term “having a sequence set forth as …”. This term is problematic because the recitation of these terms in instant claims 1-2, 7, and 9-10 renders the claim unclear by what not defining what is encompassed by “having” the sequences. Applicant has not conveyed that they are in possession of all the antibodies that are included in the broad term “having the sequence”. It is not immediately clear whether open or closed claim language is intended, Crystal Semiconductor Corp. v. Trilech Microelectronics Int’l Inc., 246 F.3d 1336, 1348, 57 USPQ2d 1953, 1959 (Fed. Cir. 2001) (term “having” in transitional phrase "does not create a presumption that the body of the claim is open"); Regents of the Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559, 1573, 43 USPQ2d 1398, 1410 (Fed. Cir. 1997) (in the context of a cDNA having a sequence coding for human PI, the term “having” still permitted inclusion of other moieties), see MPEP 2111.03. Applicant is encouraged to use transitional phrases “comprising of” or “consisting of” to define the scope of a claim with respect to what unrecited additional components, if any, are excluded from the scope of the claims.
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claim 12 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a method of treating one of the solid tumor cancers of instant claim 20 using the instantly claimed antibody, does not reasonably provide enablement for a method of treating any solid cancer using the claimed antibody. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.
MPEP § 2164.01 states:
The standard for determining whether the specification meets the enablement requirement was cast in the Supreme Court decision of Mineral Separation v. Hyde, 242 U.S. 261, 270 (1916) which postured the question: is the experimentation needed to practice the invention undue or unreasonable? That standard is still the one to be applied. In re Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988). Accordingly, even though the statute does not use the term “undue experimentation,” it has been interpreted to require that the claimed invention be enabled so that any person skilled in the art can make and use the invention without undue experimentation. In re Wands, 858 F.2d at 737, 8 USPQ2d at 1404 (Fed. Cir. 1988).
There are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is “undue.” These factors include but are not limited to:
PNG
media_image1.png
18
19
media_image1.png
Greyscale
The breadth of the claims;
PNG
media_image1.png
18
19
media_image1.png
Greyscale
The nature of the invention;
PNG
media_image1.png
18
19
media_image1.png
Greyscale
The state of the prior art;
PNG
media_image1.png
18
19
media_image1.png
Greyscale
The level of one of ordinary skill;
PNG
media_image1.png
18
19
media_image1.png
Greyscale
The level of predictability in the art;
PNG
media_image1.png
18
19
media_image1.png
Greyscale
The amount of direction provided by the inventor;
PNG
media_image1.png
18
19
media_image1.png
Greyscale
The existence of working examples; and
PNG
media_image1.png
18
19
media_image1.png
Greyscale
The quantity of experimentation needed to make or use the invention based on the content of the disclosure.
In re Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988). The factors most relevant to this rejection are 1) the amount of direction provided by the inventor, 2) the existence of working examples, and 3) undue experimentation. In the instant case, the amount of direction provided by the inventor, undue experimentation, and existence of working examples disclosed in the specification, as filed, would not be sufficient to enable the skilled artisan to make and/or use the claimed invention at the time the application was filed without undue experimentation.
(1) The amount of direction provided by the inventor - The amount of guidance or direction needed to enable an invention is inversely related to the amount of knowledge in the state of the art as well as the predictability in the art. In re Fisher, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). The “amount of guidance or direction” refers to that information in the application, as originally filed, that teaches exactly how to make or use the invention. The more that is known in the prior art about the nature of the invention, how to make, and how to use the invention, and the more predictable the art is, the less information needs to be explicitly stated in the specification. In contrast if little is known in the prior art about the nature of the invention and the art is unpredictable, the specification would need more detail as to how to make and use the invention in order to be enabling. See, e.g., Chiron Corp. v. Genentech Inc., 363 F.3d 1247, 1254, 70 USPQ2d 1321, 1326 (Fed. Cir. 2004). Due to the high level of unpredictability in treating solid cancers such as pancreatic cancer using antibody immunotherapy, the skilled artisan would need significant guidance in preparing an immunotherapy treatment with a targeted function of treating specific types of cancer. The skilled artisan recognizes that antibody binding is a wildly unpredictable endeavor that requires specificity in structure when targeting antigens and cell types. Without a proper target other than the aforementioned “solid cancer” provided by the Applicant for the invention(s), it is nearly impossible to envision and recognize all the potential types of solid cancers that the instantly claimed antibody could bind to, in addition to possessing the functionality needed to access it as a treatment for any and all cancers as claimed.
(2) The existence of working examples - As stated above the specification reasonably provides enablement for an anti-βIG-H3 antibody disclosed on pages 32-33; however, there is no showing in the specification of any means by which one skilled in the art could use the instantly claimed antibody to treat any solid cancer. Additionally, more information would be needed to ascertain how the claimed antibody would be able to work on solid cancers that do not overexpress βIG-H3 in the tumor stromal cells as is disclosed in the specification. Applicant provides examples in the instant specification of using the disclosed antibodies as a treatment against cancers which overexpress βIG-H3, but falls short to provide support for how the instantly claimed antibody can achieve the same function in any solid tumor cell(s) regardless of origin, histology, or specific metabolic pathway.
(3) Undue experimentation – The instant claims cover a treatment for all possible solid tumor cancers so long as they are capable of being bound by the instantly claimed antibody. Further, by claiming all the potential functionalities that the antibodies encompass, Applicant also claims any possible future discoveries of any factors and substances with the claimed functions. When claims depend on a recited property (i.e., treating any type of solid cancer), a fact situation comparable to Hyatt is possible, where the claim covers every conceivable structure (means) for achieving the stated property (result) while the specification discloses at most only those known to the inventor. See also Fiers v. Sugano, 984 F.2d 164, 25 USPQ2d 1601 (Fed. Cir. 1993) and MPEP §2164.08(a). Therefore, the specification fails to provide enough guidance for one skilled in the art on how to practice the instant method except for the instant examples, thereby requiring trial and error experimentation to identify which solid cancers would satisfy meeting the functional limitations of the claims.
As set forth above, inadequate guidance is presented in the specification to overcome the obstacles in practicing the claimed invention in its full scope. The test of enablement is not whether any experimentation is necessary, but whether, if experimentation is necessary, it is undue. Given the tremendous breath of scope involving the instant claims, it would require undue experimentation for one of skill in the art to practice the claimed invention in its full scope. Therefore, the specification fails to provide enough guidance for one skilled in the art on how to practice the instant method, thereby requiring trial and error experimentation to identify antibodies or recombinant proteins meeting the functional limitations of the claims. The general knowledge and level of skill in the art do not supplement the omitted description because specific, not general, guidance is what is needed.
In conclusion upon careful consideration of the Wands factors that are used to determine whether undue experimentation is required to practice an invention, the amount of direction provided by the inventor, undue experimentation, and the working examples provided, as filed, is not deemed sufficient to enable the skilled artisan to make and/or use the invention commensurate in scope with the instant claims at the time the application was filed without undue experimentation.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SELAM BERHANE whose telephone number is (571)272-6138. The examiner can normally be reached Monday - Friday, 9-5.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Stucker can be reached at 571-272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SELAM BERHANE/Examiner, Art Unit 1675
/AURORA M FONTAINHAS/Primary Examiner, Art Unit 1675